TF
Highly rated in
46
conditions

Dr. Tatyana A. Feldman

Regional Cancer Care Associates, LLC
Hackensack, NJ
Highly rated in
46
conditions
Specialties:Hematology Oncology | Oncology
Experience:31 Years
Clinical Trials:Currently Recruiting for 4 Trials
Accepts:New PatientsMedicare
Highly rated in
46
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Tatyana A. Feldman's experience treating your condition:
About Dr. Tatyana A. Feldman

Tatyana Feldman is a Hematologist Oncology specialist and an Oncologist in Hackensack, New Jersey. Feldman has been practicing medicine for over 31 years and is highly rated in 46 conditions, according to our data. Her top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in New Jersey. Feldman is currently accepting new patients.

Her clinical research consists of co-authoring 68 peer reviewed articles and participating in 22 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Tatyana A. Feldman it is best to call her office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
92 2nd St, Hackensack, NJ 07601
Background & Education
Graduate Institution
Other, 1992
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in NJ
Hospital Affiliations
JFK Medical Center
Hackensack University Medical Center
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
Enrollment Status: Recruiting
Publish Date: August 16, 2022
Intervention Type: Drug, Biological
Study Drugs: PembrolizumabPralatrexate
Study Phase: Phase 1/Phase 2
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Enrollment Status: Recruiting
Publish Date: July 19, 2022
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Recruiting
Publish Date: November 26, 2021
Intervention Type: Other, Drug, Biological
Study Drugs: BleomycinBrentuximabDacarbazineDoxorubicinNivolumabVinblastine
Study Phase: Phase 2
A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered VRx-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies
Enrollment Status: Recruiting
Publish Date: July 28, 2021
Intervention Type: Drug
Study Drugs: VRx-3996Valganciclovir
Study Phase: Phase 1/Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Active, not recruiting
Publish Date: December 06, 2022
Intervention Type: Drug
Study Drugs: BrentuximabDoxorubicinVinblastineDacarbazineNivolumabFilgrastim
Study Phase: Phase 2
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Enrollment Status: Active, not recruiting
Publish Date: December 06, 2022
Intervention Type: Drug
Study Drugs: IpilimumabNivolumab
Study Phase: Phase 1/Phase 2
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Enrollment Status: Active, not recruiting
Publish Date: November 25, 2022
Intervention Type: Biological
Study Drugs: Lisocabtagene MaraleucelIbrutinib
Study Phase: Phase 1/Phase 2
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Active, not recruiting
Publish Date: November 25, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: CarboplatinEtoposideIfosfamideLenalidomideRituximab
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: BrentuximabNivolumab
Study Phase: Phase 1/Phase 2
Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)
Enrollment Status: Active, not recruiting
Publish Date: October 10, 2022
Intervention Type: Drug
Study Drugs: ABT-199IbrutinibRituximab
Study Phase: Phase 1
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Active, not recruiting
Publish Date: July 28, 2022
Intervention Type: Drug
Study Drugs: TTI-621Rituximab
Study Phase: Phase 1
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Enrollment Status: Active, not recruiting
Publish Date: July 22, 2022
Intervention Type: Drug, Biological
Study Drugs: BrentuximabNivolumab
Study Phase: Phase 2
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: July 08, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: BrentuximabDacarbazineDoxorubicinNivolumabVinblastine
Study Phase: Phase 2
A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: June 09, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: PembrolizumabVorinostat
Study Phase: Phase 1
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas
Enrollment Status: Active, not recruiting
Publish Date: June 06, 2022
Intervention Type: Drug, Other
Study Drugs: BrentuximabCyclophosphamideDoxorubicinDoxorubicin HydrochlorideEtoposideEtoposide PhosphatePrednisone
Study Phase: Phase 2
A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: March 18, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: BrentuximabNivolumab
Study Phase: Phase 2
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
Enrollment Status: Terminated
Publish Date: March 13, 2019
Intervention Type: Biological
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)
Enrollment Status: Unknown status
Publish Date: February 04, 2014
Intervention Type: Drug
Study Drug: Revlimid
Study Phase: Phase 1/Phase 2
View 16 Less Clinical Trials -
68 Total Publications
ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) -Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 27, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
AM
Dr. Alison J. Moskowitz
Hematology Oncology | Hematology | Oncology
Highly rated in
34
conditions
Hematology Oncology
Hematology
Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 9.7 mi

Alison Moskowitz is a Hematologist Oncology specialist and a Hematologist in New York, New York. Moskowitz has been practicing medicine for over 20 years and is highly rated in 34 conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in New York. Moskowitz is currently accepting new patients.

GR
Gail J. Roboz
Dr. Gail J. Roboz
Oncology | Hematology Oncology | Hematology
Highly rated in
40
conditions
Oncology
Hematology Oncology
Hematology

NewYork-Presbyterian Healthcare System

Cardiology At Weill Cornell Medical Center, Starr Pavilion

520 E 70th St, 
New York, NY 
 9.7 mi

Gail Roboz is an Oncologist and a Hematologist Oncology expert in New York, New York. Roboz has been practicing medicine for over 29 years and is highly rated in 40 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in New York.

RF
Richard R. Furman
Dr. Richard R. Furman
Oncology | Hematology Oncology | Hematology
Highly rated in
34
conditions
Oncology
Hematology Oncology
Hematology

NewYork-Presbyterian Healthcare System

Richard Silver

520 E 70th St, 
New York, NY 
 9.7 mi

Richard Furman is an Oncologist and a Hematologist Oncology expert in New York, New York. Furman has been practicing medicine for over 30 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in New York.